The TJX Companies, Inc. Announces Quarterly Common Stock Dividend
Get Alerts TJX Hot Sheet
Join SI Premium – FREE
FRAMINGHAM, Mass.--(BUSINESS WIRE)-- The TJX Companies, Inc. (NYSE: TJX) today announced the declaration of a quarterly dividend on its common stock of $.3325 per share payable November 30, 2023, to shareholders of record on November 9, 2023.
About The TJX Companies, Inc.
The TJX Companies, Inc. is the leading off-price retailer of apparel and home fashions in the U.S. and worldwide. As of July 29, 2023, the end of the Company’s second quarter, the Company operated a total of 4,884 stores in nine countries, the United States, Canada, the United Kingdom, Ireland, Germany, Poland, Austria, the Netherlands, and Australia, and seven e-commerce sites. These include 1,305 T.J. Maxx, 1,190 Marshalls, 907 HomeGoods, 83 Sierra, and 49 Homesense stores, as well as tjmaxx.com, marshalls.com, homegoods.com, and sierra.com, in the United States; 299 Winners, 154 HomeSense, and 106 Marshalls stores in Canada; 636 T.K. Maxx and 79 Homesense stores, as well as tkmaxx.com, tkmaxx.de, and tkmaxx.at in Europe; and 76 T.K. Maxx stores in Australia. TJX’s press releases and financial information are available at TJX.com.
Important Information at Website
The Company routinely posts information that may be important to investors in the Investors section at TJX.com. The Company encourages investors to consult that section of its website regularly.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230919638829/en/
Debra McConnell
Global Communications
(508) 390-2323
Source: The TJX Companies, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European
- OCAL Financial Launches Video-First Brand Campaign With DIBO Marketing and Engages Signal Capital for Investor Relations
- Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share